Halozyme Therapeutics Inc. (HALO: Quote) and Baxter International Inc. (BAX: Quote) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has granted a Positive Opinion to Baxter for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies.
Halozyme Therapeutics gapped up sharply Friday and climbed above the session's narrow range in the final 2 hours of trade. Shares finished up by 1.63 at $6.90 on the highest volume in 3 months. The stock broke out to nearly a 2-month high and re-crossed both its 50 and 200-day moving averages.
by RTT Staff Writer
For comments and feedback: email@example.com